These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34982278)

  • 1. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.
    Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A
    Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.
    Yu S; Murph MM; Lu Y; Liu S; Hall HS; Liu J; Stephens C; Fang X; Mills GB
    J Natl Cancer Inst; 2008 Nov; 100(22):1630-42. PubMed ID: 19001604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA
    Park J; Jang JH; Oh S; Kim M; Shin C; Jeong M; Heo K; Park JB; Kim SR; Oh YS
    Cell Signal; 2018 Apr; 44():138-147. PubMed ID: 29329782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPA
    Wang F; Liu S; Pei J; Cai L; Liu N; Liang T; Dong X; Cong X; Chun J; Chen J; Hu S; Chen X
    Theranostics; 2020; 10(24):10892-10907. PubMed ID: 33042260
    [No Abstract]   [Full Text] [Related]  

  • 6. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
    Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
    Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid signaling via LPA
    Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
    Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.
    Chen H; Wu X; Pan ZK; Huang S
    Cancer Res; 2010 Dec; 70(23):9979-90. PubMed ID: 21118970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.
    Kim EK; Park JM; Lim S; Choi JW; Kim HS; Seok H; Seo JK; Oh K; Lee DS; Kim KT; Ryu SH; Suh PG
    J Biol Chem; 2011 Jul; 286(27):24036-45. PubMed ID: 21602274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
    David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
    PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
    Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
    J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis.
    David M; Ribeiro J; Descotes F; Serre CM; Barbier M; Murone M; Clézardin P; Peyruchaud O
    Int J Oncol; 2012 Apr; 40(4):1133-41. PubMed ID: 22200658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
    Tanyi J; Rigó J
    Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
    Fan Q; Cai Q; Xu Y
    Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of endothelial cells in the regulation of cell motility via lysophosphatidic acid receptor-2 (LPA
    Minami K; Ueda N; Ishimoto K; Kurisu R; Takamoto M; Ikeda H; Tsujiuchi T
    Exp Mol Pathol; 2021 Feb; 118():104596. PubMed ID: 33347862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer.
    Ha JH; Radhakrishnan R; Nadhan R; Gomathinayagam R; Jayaraman M; Yan M; Kashyap S; Fung KM; Xu C; Bhattacharya R; Mukherjee P; Isidoro C; Song YS; Dhanasekaran DN
    Cancer Lett; 2024 Jun; 591():216891. PubMed ID: 38642607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidic acid stimulates cell growth by different mechanisms in SKOV-3 and Caov-3 ovarian cancer cells: distinct roles for Gi- and Rho-dependent pathways.
    Hurst JH; Hooks SB
    Pharmacology; 2009; 83(6):333-47. PubMed ID: 19420982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.
    Zuckerman V; Sokolov E; Swet JH; Ahrens WA; Showlater V; Iannitti DA; Mckillop IH
    Oncotarget; 2016 Jan; 7(3):2951-67. PubMed ID: 26701886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells.
    Takahashi K; Fukushima K; Tanaka K; Minami K; Ishimoto K; Otagaki S; Fukushima N; Honoki K; Tsujiuchi T
    Exp Cell Res; 2018 Aug; 369(2):316-324. PubMed ID: 29859140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.